| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
NextCure, Inc.
13D/A
NXTC · 65343E207
|
7.1% |
3/5/2026
Event 12/19/2025
|
||||
| Sofinnova Venture Partners IX, L.P. ("SVP IX") | 7.1% | |||||
| Sofinnova Management IX, L.L.C. ("SM IX") | 7.1% | |||||
| Dr. James I. Healy ("Healy") | 7.1% | |||||
| Schedule 13G · 1 security · passive | ||||||
|
ArriVent Biopharma, Inc.
13G/A
AVBP · 04272N102
|
4.1% |
3/5/2026
Event 12/31/2025
|
||||
| Sofinnova Venture Partners XI, L.P. ("SVP XI") | 4.1% | |||||
| Sofinnova Management XI, L.P. ("SM XI LP") | 4.1% | |||||
| Sofinnova Management XI, L.L.C. ("SM XI LLC") | 4.1% | |||||
| Dr. James I. Healy ("Healy") | 4.1% | |||||
| Dr. Maha Katabi ("Katabi") | 4.1% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.